ÑÎËá°Âµ¤Î÷¡ÓëÆäËüÒ©ÎïÅäÎéµÄÎȶ¨ÐÔ
×÷ÕߣºÍõÃ÷ÖÙ
µ¥Î»£ººþ±±Ïå·®ÊÐÖÐÐÄҽԺҩѧ²¿ Ïå·® 441021
¹Ø¼ü´Ê£º
ÖйúÏÖ´úÓ¦ÓÃҩѧ000233 ÑÎËá°Âµ¤Î÷¡(Ondansetron hydrochloride,Ond)ΪӢ¹ú¸ðÀ¼Ëع«Ë¾1989Ä꿪 ·¢³É¹¦µÄ¸ß¶ÈÑ¡ÔñÐÔ5-HT3ÊÜÌåÞ׿¹¼Á£¬ÉÌÆ·ÃûΪÊิÄþ(zofran)£¬ÓÃÓÚ·ÅÁÆ¡¢»¯ÁÆʱÕò ÍÂЧ¹ûÏÔÖø¡£ÎÒ¹úÄþ²¨ÌìºâÖÆÒ©³§×Ô1996ÄêÕýʽÉú²ú£¬ÉÌÆ·ÃûÊ൤¡£ÓÉÓÚÖ×Áö»¼ÕßÓÃÒ©µÄ¸´ ÔÓÐÔ£¬Ðí¶àѧÕß¾¹ÏàÑо¿ÁËOnd³£ÓÃŨ¶È(0.03¡«0.3mg/ml)ÏÂÓëÆäËüÒ©ÎïµÄÅäÎéÐÔ£¬±¾ÎÄÓè ÒÔ×ۺϽéÉÜ(¼û±í1)£¬ÒÔÀûÓÃÒ©²Î¿¼¡£
±í1 ÑÎËá°Âµ¤Î÷¡ÓëÆäËüÒ©ÎïÅäÎéµÄÎȶ¨ÐÔ ÅäÎéÒ©Îï
Ũ¶È/mg.ml-1
, http://www.100md.com
ÈÜý
OndŨ¶È
/mg.ml-1
ÈÝÆ÷
Öü´æÌõ¼þ
¹Û²ì
Ö¸±ê
Îȶ¨
ʱ¼ä
²Î¿¼
ÎÄÏ×
10%ÆÏÌÑÌÇ(10%GS)
, °ÙÄ´Ò½Ò© 0.08
d
ÊÒÎÂ
Y
>24h
1
5%ÆÏÌÑÌÇ(5%GS)
0.03£¬0.3
-20¡æ,5¡æ,25¡æ
Y
> 24h
2£¬3
ÉúÀíÑÎË®(NS)
, °ÙÄ´Ò½Ò©
0.03£¬0.08£¬0.3
d
-20¡æ£¬5¡æ£¬25¡æ
Y
>24h
1£¬2
ÆÏÌÑÌÇÂÈ»¯ÄÆ×¢ÉäÒº
0.08
d
ÊÒÎÂ
Y
>24h
1
, °ÙÄ´Ò½Ò©
¸´·½ÂÈ»¯ÄÆ×¢ÉäÒº
0.08
d
ÊÒÎÂ
Y
>24h
1
ÑÎËᰢùËØ
0.1£¬2
5%GS
0.03£¬0.3
a
ÊÒΣ¬ÈÕ¹âµÆÏÂ
, °ÙÄ´Ò½Ò©
Y
>24h
4
°¢ÌÇ°ûÜÕ
0.2£¬40
5%GS
0.03£¬0.3
a
ÊÒΣ¬ÈÕ¹âµÆÏÂ
Y
>24h
4
1¦¤
, °ÙÄ´Ò½Ò©
´ï¿¨°Íàº
1£¬3
5%GS
0.03£¬0.3
a,c
4¡æ£¬30¡æ£¬ÈÕ¹âµÆ ÏÂ
Y
4¡«8h
4£¬5
ÒÀÍв´ÜÕ
0.1£¬0.4
5%GS
0.03£¬0.3
, °ÙÄ´Ò½Ò©
a
ÊÒΣ¬ÈÕ¹âµÆÏÂ
Y
>24h
4
¼×°±µûßÊ
0.5£¬6
5%GS
0.03£¬0.3
a
ÊÒΣ¬ÈÕ¹âµÆÏÂ
Y
>24h
, http://www.100md.com
4
2¦¤
ÁòË᳤´ºÐ¼î
0.014£¬0.028
NS
0.048£¬0.096
a,c
4¡æ£¬3 0¡æ
Y
>24h
5
»·Á×õ£°·
0.3£¬2
, http://www.100md.com
5%GS£¬NS
0.05£¬0.4
4¡æ£¬25¡æ
Y
>4d
6£¬7
×Ïɼ´¼
1.2
5%GS
0.3£¬7.29
b
23¡æ
Y
, °ÙÄ´Ò½Ò©
>4h
8£¬9
˳²¬
0.200£¬0.455
NS
1.091£¬0.480
a
2¡«8¡æ£¬30¡æ
Y
>24h
10
àçÌæßß
1
, °ÙÄ´Ò½Ò©
5%GS
1
b
23¡æ£»¸ß¡¢µÍÕնȹâ
X
>4h
11
ßßÀÎ÷ÁÖ-Ëûßò°Í̹
40-5£¬80-10
NS
0.03£¬0.1£¬0.3
b
23 ¡æ,ÊÒ¹â
, °ÙÄ´Ò½Ò©
Y
>4h
12
°±ÇúÄÏ
20£¬40
5%GS
0.015£¬0.15£¬1
b
25¡æ
X
>4h
13£¬14
Í·æßËþÆ붨(̼ËáÄÆÑÎ)
, °ÙÄ´Ò½Ò©
20
5%GS
0.015£¬0.15
b
25¡æ
X
>4h
13
Í·æßßòßøÄÆ
10
5%GS
0.015£¬0.15
b
, http://www.100md.com
25¡æ
X
>4h
1 3
·ú¿µßò
1
NS
0.015£¬0.15
b
25¡æ
X
>4h
13
, http://www.100md.com 3¦¤
Ã×ŵÅäÄÜ(meropenam)
1£¬20£¬50
NS
1
b,d
ÊÒΣ¬ÈÕ¹âµÆ ÏÂ
X
0(³Áµí)
15
Í·æßÃÀßòÄÆ
100
NS
, °ÙÄ´Ò½Ò©
2
a,b,c
ÊÒΣ¬ÈÕ¹âµÆÏÂ
X
>1h
16
ÁòËáÂð·È
1
NS
0.1£¬1.0
4¡æ,22¡æ
X
>31d
, °ÙÄ´Ò½Ò©
17
ÑÎËá¶þÇâÂð·È
0.5
NS
0.1£¬1.0
4¡æ,22¡æ
X
>31d
17
remifentanil hydrochloride
0.025£¬0.25
NS
, http://www.100md.com 1
b
23¡æ
X
>4h
18
±½Ì¼Ëá˳°¢Çú¿âï§
0.1£¬2£¬5
5%GS
1
b
23¡æ£¬¸ßµÍÕնȹâ
X
, °ÙÄ´Ò½Ò©
>4h
19
TPN(»òPN)
NS
0.03£¬0.3£¬1
b
ÊÒΣ¬ÈÕ¹âµÆÏÂ
Y
>4 8h
20£¬21
4¦¤
CsA
1.5
, °ÙÄ´Ò½Ò©
NS
0.32
b,d
ÊÒΣ¬ÈÕ¹âµÆÏÂ
X
?
22
ÑÎËá¶à°Í°·
0.8
NS
0.32
b,d
ÊÒΣ¬ÈÕ¹âµÆÏÂ
, °ÙÄ´Ò½Ò©
X
>5h
22
¸ÎËØÄÆ
100u/ml
NS£¬5%GS
0.32
b,d
ÊÒΣ¬ÈÕ¹âµÆÏÂ
X
>5h
22
5¦¤
, °ÙÄ´Ò½Ò©
Æ»¹ûÖ¡¢éÙÖ¡¢¹û¾Æ¡¢Ó£ÌÒ
ÒûÁÏ¡¢Ì¼ËáÀàÈíÒûÁÏ
0.067-2
d
-3¡«28¡æ
Y
>1h
23£¬24
ÑÎËáÀ×ÄáÌ涡
0.2£¬2.0
5%GS
0.03£¬0.1£¬0.3
, °ÙÄ´Ò½Ò©
b
23¡æ
Y
>4h
8£¬25
6¦¤
µØÈûÃ×ËÉ
0.20£¬0.40
NS£¬5%GS
0.10£¬0.2£¬0.4£¬0.64[ HT6¡±¡½
a
2¡«6¡æ£¬23¡æ
Y
, °ÙÄ´Ò½Ò©
>48h
26¡«28
ÀÍÀÎ÷ãú
0.004
5%GS
0.016,0.08
d
25¡æ
Y
>24h
26
aldesleukin(ÖØ×é°×½éËØ-2)
33800IU/ml
, °ÙÄ´Ò½Ò©
5%GS
0.7
b
ÊÒΣ¬ ÈÕ¹âµÆÏÂ
Z
>2h
29
amifostine
10
5%GS
1
b
23¡æ
, °ÙÄ´Ò½Ò©
X
>4h
30
×¢£ºa-Ö±½Ó»ìºÏÓÚPVC´üÄÚ£»b-Ä£ÄâÊäҺװÖÃY²¿µÈÌå»ý»ìºÏÖüÓÚPVC´üÖÐ £»c-ÔÚ¾Û ÒìÎì¶þÏ©ÊäÒº±ÃÒ©³ØÖУ»d-²£Á§ÈÝÆ÷£»X-Íâ¹Û£»Y-Íâ¹Û¼°º¬Á¿£»Z-Íâ¹Û¡¢º¬Á¿¼°ÉúÎïЧ¼Û£» 1¦¤-Ond¡¢ÑÎËᰢùËØ¡¢´ï¿¨°ÍàºÈýÒ©ÅäÎ飬30¡æ¡¢ÈÕ¹âµÆÏ¡¢PVC´üÄÚÎȶ¨4¡«8h£¬¾ÛÒìÎì ¶þÏ©ÊäÒº±ÃÒ©³ØÖÐÎȶ¨24hÒÔÉÏ£»2¦¤-Ond¡¢ÑÎËᰢùËØ¡¢ÁòË᳤´ºÐ¼îÈýÒ©ÅäÎ飬30¡æ£¬ÈÕ ¹âµÆÏ£¬a»òcÈÝÆ÷ÄÚ¾ùÎȶ¨24hÒÔÉÏ£»3¦¤-Ond 1mg/mlÓëÃ×ŵÅäÄÜ1mg/ml NSÈÜÒºÅäÎéÎÞ³Áµí £»4¦¤-CsAÔÚNSÖÐ΢Á£³¬ÏÞ£¬¼ÓÈëOndºó΢Á£ÎÞÃ÷ÏÔÔö¼Ó£»5¦¤-Ond¼ÓÈëÈȲè(75¡«85¡æ)Öм´ ¿Ì±ä»ì×Ç£»6¦¤-¸ßŨ¶ÈµÄOnd(0.64mg/ml)ÓëµØÈûÃ×ËÉ(0.40mg/ml)ÔÚ¾Û±ûϩעÉäÆ÷ÖгÁµí(µÍ Ũ¶ÈÎÞ)£¬¸÷Ũ¶ÈÔÚ¹¤Òµ¾ÛÖ¬CR3´üÄÚÎȶ¨48hÒÔÉÏ
, http://www.100md.com
Óɸ½±í¿ÉÖª£¬OndÔÚ³£ÓÃŨ¶ÈÏ¿ÉÓëÐí¶àÒ©ÎïÅäÎéʹÓã¬Õâ¶Ô¼õÉÙ»¼Õß±»´©´Ì´ÎÊý¡¢Ò½ÎñÈË Ô±¹¤×÷Á¿¡¢»¼Õß²»±ØÒªÒºÌåÉãÈë¾ù¾ßÓлý¼«µÄÁÙ´²ÒâÒå¡£µ«Ó¦ÓÃÖÐӦעÒâÅäÎéÔÊÐíµÄŨ¶ÈºÍ Îȶ¨Ê±ÏÞ¡£OndÒ»°ã²»ÄÜÓëÃ×ŵÅäÄÜÅäÎ飬ÓëµØÈûÃ×ËÉÅäÎé²»ÄÜʹÓþ۱ûϩעÉäÆ÷¾ß£¬Ond¿É ¿Ú·þÓÃÒ©µ«²»ÄܼÓÈëÈȲèÖÐÒûÓã¬ÊÇ·ñÄÜÓë»·æßËØA(CsA)ÅäÎéÉв»Ã÷È·¡£
²Î¿¼ÎÄÏ×
1£¬Ðì¼ÃƼ£¬ÕŹ𷼣¬Õżø.°Âµ¤Î÷¡עÉäÒºÔÚ4ÖÖ ÊäÒºÖеÄÎȶ¨ÐÔ.ÖйúÁÙ´²Ò©Ñ§ÔÓÖ¾£¬1997£¬6(1)¡Ã31.
2£¬Bosso JA,Prince RA,Fox JL.Stability of on dansetron hydrochloride in injectable solutions at -20,5,25¡æ.Am J Hosp Pharm,19 92,49¡Ã2225.
3£¬Thee SS,Jeona EWS,Chin A,et al.Stability of ondanstron hydrochloride stored in a disposable elastomeric in fu sion device at 4¡æ.Am J Hosp Pharm,1993,50¡Ã1920.
, °ÙÄ´Ò½Ò©
4£¬ÍõÃ÷ÖÙÕª.ÑÎËá°Âµ¤Î÷¡ÓëÎåÖÖ¿¹Ö×ÁöÒ©µÄÅäÎé Îȶ¨ÐÔ.¹úÍâÒ½Ò©-ºÏ³ÉÒ©¡¢Éú»¯Ò©¡¢ÖƼÁ·Ö²á£¬1997£¬18(3)¡Ã189.
5£¬Stewart JT,Warren FW,King DT,et al.Stability of ondansetron hydrochloride,doxorubicin hydrochloride,and dacar bazine or vincristine sulfate in elastomeric portable infusion devices and polyv inyl chloride bags.Am J Health-Syst Pharm,1997,54¡Ã915.
6£¬Fleming RA,Olsen DJ,Savage PD,et al .Stability of ondansetron hydrochloride and cyclophosphamide.Am J Health- Syst Pharm,1995,52(5)¡Ã516.
, °ÙÄ´Ò½Ò©
7£¬Ðì¼ÃƼ£¬Õżø£¬ÕŹð·¼.°ºµ¤Ë¾Çí×¢Éä¼ÁÓë»·Á× õ£°·×¢Éä¼ÁµÄÅäÎéÎȶ¨ÐÔ.ÖйúҽԺҩѧÔÓÖ¾£¬1997£¬17(6)¡Ã263.
8£¬Burm JP,Jhee SS,Chin A,et al. Stability of paclitaxel with ondansetron hydrochloride or ranitidine hydrochlori de during simulated Y-site administration.Am J Hosp Pharm,1994,51¡Ã1201.
9£¬Trissel LA,Martinez JF.Turbidimetric as sessment of the compatibility of taxol with 42 other drugs during simulated Y-s ite injection.Am J Hosp Pharm,1993,50¡Ã300.
, °ÙÄ´Ò½Ò©
10£¬Henry DW,Marshall JL,Nazzaro D,et al .Stability of cisplatin and ondansetron hydrochloride in admixtures for continuo us infusion.Am J Health-Syst Pharm,1995,52¡Ã2570.
11£¬Trissel LA,Martinez JF.Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.Am J H ealth-Syst Pharm,1996,53¡Ã1041.
12£¬Chung KC,Moon YSK,Chin A,et al.Compa tibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration.Am J Health-Syst Pharm,1995,52¡Ã1554.
, °ÙÄ´Ò½Ò©
13£¬Bosso JA,Prince RA,Fox JL,et al.Compatibility of ondansetron hydrochloride with fluconazole,ceftazidime,azt reonam,and cefazolin sodium under simulated Y-site conditions.Am J Hosp Pharm,1 994,51¡Ã389.
14£¬Trissel LA,Martinez JF.Compatibility of aztreona m with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm,1995,52¡Ã1086.
15£¬Patel PR.Compatibility of meropenam with commonl y used injectable drugs.Am J Health-Syst Pharm,1996,53¡Ã2853.
, °ÙÄ´Ò½Ò©
16£¬Hutchings SR,Rusho Wj,Tyler LS.Compatibility of cefmetazole sodium with commonly used drugs during Y-Site delivery.Am J Health -Syst Pharm,1996,53¡Ã2185.
17£¬Trissel LA,Xu QY,Martinez JF,et al.C ompatibility and stability of ondansetron hydrochloride with morphine sulfate an d with hydromorphine hydrochloride in 0.9% sodium chloride injection at 4,22,and 32¡æ.Am J Hosp Pharm,1994,51¡Ã2142.
18£¬Trissel LA,Gilbert DL,Martinez JF,et al.Compatibility of remifentanil hydrochloride with selected drugs during simul ated Y-site administration.Am J Health-Syst Pharm,1997,54¡Ã2192.
, °ÙÄ´Ò½Ò©
19£¬Trissel LA,Martinez JF,Gilbert DL.Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administr ation.Am J Health-Syst Pharm,1997,54¡Ã1735.
20£¬Kirkham JC,Rutherford ET,Cunningham GN,et al.Stability of ondansetron hydrochloride in a total parenteral nutrient a dmixture.Am J Health-Syst Pharm,1995,52¡Ã1557
21£¬Trissel LA,Gilbert DL,Martinez JF,et al.Compatibility of parenteral nutrient solutions with selected drugs during si mulated Y-site administration.Am J Health-Syst Pharm,1997,54¡Ã1295.
, http://www.100md.com
22£¬Najari Z,Rusho Wj.Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.Am J Health-Syst Pharm,19 97,54¡Ã181.
23£¬Graham CL,Dukes GE,Fox JL,et al.Stab ility of ondansetron hydrochloride injection in extemporaneously prepared oral s olutions.Am J Hosp Pharm,1993,50¡Ã106.
24£¬Yamreudeewong W,Danthi SN,Hill RA,et al.Stability of ondansetron hydrochloride injection in various beverages.Am J H ealth-Syst Pharm,1995,52¡Ã2011.
, http://www.100md.com
25£¬Pompilio FM,Fox JL,Inagaki K,et al.S tability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazo le during simulated Y-site administration.Am J Hosp Pharm,1994,51¡Ã394.
26£¬Mcguire TR,Narducci WA,Fox JL.Compatibility an d stability of ondansetron hydrochloride,dexamethasone,and lorazepam in injectab le solutions.Am J Hosp Pharm,1993,50(7)¡Ã1410.
27£¬Evrard B,Ceccato A,Gaspard O,et al.S tability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride injection and in 5% dextrose injection.Am J Health-Syst Pharm, 1997,54¡Ã1065.
, http://www.100md.com
28£¬Hagan RL,Mallett MS,Fox JL.Stability of ondanset ron hydrochloride and dexamethasone sodium phosphate in infusion bags and syring es for 32 days.Am J Health-Syst Pharm,1996,53¡Ã1431
29£¬Alex S,Gupta SL,Minor JR,et al.Compa tibility and activity of aldesleukin(recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration:Evaluation of three metho ds.Am J Health-Syst Pharm,1995,52¡Ã2423.
30£¬Trissel LA,Martinez JF.Compatibility of amifosti ne with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm,1995,52¡Ã2208.
ÊÕ¸åÈÕÆÚ£º1998-04-06, http://www.100md.com
µ¥Î»£ººþ±±Ïå·®ÊÐÖÐÐÄҽԺҩѧ²¿ Ïå·® 441021
¹Ø¼ü´Ê£º
ÖйúÏÖ´úÓ¦ÓÃҩѧ000233 ÑÎËá°Âµ¤Î÷¡(Ondansetron hydrochloride,Ond)ΪӢ¹ú¸ðÀ¼Ëع«Ë¾1989Ä꿪 ·¢³É¹¦µÄ¸ß¶ÈÑ¡ÔñÐÔ5-HT3ÊÜÌåÞ׿¹¼Á£¬ÉÌÆ·ÃûΪÊิÄþ(zofran)£¬ÓÃÓÚ·ÅÁÆ¡¢»¯ÁÆʱÕò ÍÂЧ¹ûÏÔÖø¡£ÎÒ¹úÄþ²¨ÌìºâÖÆÒ©³§×Ô1996ÄêÕýʽÉú²ú£¬ÉÌÆ·ÃûÊ൤¡£ÓÉÓÚÖ×Áö»¼ÕßÓÃÒ©µÄ¸´ ÔÓÐÔ£¬Ðí¶àѧÕß¾¹ÏàÑо¿ÁËOnd³£ÓÃŨ¶È(0.03¡«0.3mg/ml)ÏÂÓëÆäËüÒ©ÎïµÄÅäÎéÐÔ£¬±¾ÎÄÓè ÒÔ×ۺϽéÉÜ(¼û±í1)£¬ÒÔÀûÓÃÒ©²Î¿¼¡£
±í1 ÑÎËá°Âµ¤Î÷¡ÓëÆäËüÒ©ÎïÅäÎéµÄÎȶ¨ÐÔ ÅäÎéÒ©Îï
Ũ¶È/mg.ml-1
, http://www.100md.com
ÈÜý
OndŨ¶È
/mg.ml-1
ÈÝÆ÷
Öü´æÌõ¼þ
¹Û²ì
Ö¸±ê
Îȶ¨
ʱ¼ä
²Î¿¼
ÎÄÏ×
10%ÆÏÌÑÌÇ(10%GS)
, °ÙÄ´Ò½Ò© 0.08
d
ÊÒÎÂ
Y
>24h
1
5%ÆÏÌÑÌÇ(5%GS)
0.03£¬0.3
-20¡æ,5¡æ,25¡æ
Y
> 24h
2£¬3
ÉúÀíÑÎË®(NS)
, °ÙÄ´Ò½Ò©
0.03£¬0.08£¬0.3
d
-20¡æ£¬5¡æ£¬25¡æ
Y
>24h
1£¬2
ÆÏÌÑÌÇÂÈ»¯ÄÆ×¢ÉäÒº
0.08
d
ÊÒÎÂ
Y
>24h
1
, °ÙÄ´Ò½Ò©
¸´·½ÂÈ»¯ÄÆ×¢ÉäÒº
0.08
d
ÊÒÎÂ
Y
>24h
1
ÑÎËᰢùËØ
0.1£¬2
5%GS
0.03£¬0.3
a
ÊÒΣ¬ÈÕ¹âµÆÏÂ
, °ÙÄ´Ò½Ò©
Y
>24h
4
°¢ÌÇ°ûÜÕ
0.2£¬40
5%GS
0.03£¬0.3
a
ÊÒΣ¬ÈÕ¹âµÆÏÂ
Y
>24h
4
1¦¤
, °ÙÄ´Ò½Ò©
´ï¿¨°Íàº
1£¬3
5%GS
0.03£¬0.3
a,c
4¡æ£¬30¡æ£¬ÈÕ¹âµÆ ÏÂ
Y
4¡«8h
4£¬5
ÒÀÍв´ÜÕ
0.1£¬0.4
5%GS
0.03£¬0.3
, °ÙÄ´Ò½Ò©
a
ÊÒΣ¬ÈÕ¹âµÆÏÂ
Y
>24h
4
¼×°±µûßÊ
0.5£¬6
5%GS
0.03£¬0.3
a
ÊÒΣ¬ÈÕ¹âµÆÏÂ
Y
>24h
, http://www.100md.com
4
2¦¤
ÁòË᳤´ºÐ¼î
0.014£¬0.028
NS
0.048£¬0.096
a,c
4¡æ£¬3 0¡æ
Y
>24h
5
»·Á×õ£°·
0.3£¬2
, http://www.100md.com
5%GS£¬NS
0.05£¬0.4
4¡æ£¬25¡æ
Y
>4d
6£¬7
×Ïɼ´¼
1.2
5%GS
0.3£¬7.29
b
23¡æ
Y
, °ÙÄ´Ò½Ò©
>4h
8£¬9
˳²¬
0.200£¬0.455
NS
1.091£¬0.480
a
2¡«8¡æ£¬30¡æ
Y
>24h
10
àçÌæßß
1
, °ÙÄ´Ò½Ò©
5%GS
1
b
23¡æ£»¸ß¡¢µÍÕնȹâ
X
>4h
11
ßßÀÎ÷ÁÖ-Ëûßò°Í̹
40-5£¬80-10
NS
0.03£¬0.1£¬0.3
b
23 ¡æ,ÊÒ¹â
, °ÙÄ´Ò½Ò©
Y
>4h
12
°±ÇúÄÏ
20£¬40
5%GS
0.015£¬0.15£¬1
b
25¡æ
X
>4h
13£¬14
Í·æßËþÆ붨(̼ËáÄÆÑÎ)
, °ÙÄ´Ò½Ò©
20
5%GS
0.015£¬0.15
b
25¡æ
X
>4h
13
Í·æßßòßøÄÆ
10
5%GS
0.015£¬0.15
b
, http://www.100md.com
25¡æ
X
>4h
1 3
·ú¿µßò
1
NS
0.015£¬0.15
b
25¡æ
X
>4h
13
, http://www.100md.com 3¦¤
Ã×ŵÅäÄÜ(meropenam)
1£¬20£¬50
NS
1
b,d
ÊÒΣ¬ÈÕ¹âµÆ ÏÂ
X
0(³Áµí)
15
Í·æßÃÀßòÄÆ
100
NS
, °ÙÄ´Ò½Ò©
2
a,b,c
ÊÒΣ¬ÈÕ¹âµÆÏÂ
X
>1h
16
ÁòËáÂð·È
1
NS
0.1£¬1.0
4¡æ,22¡æ
X
>31d
, °ÙÄ´Ò½Ò©
17
ÑÎËá¶þÇâÂð·È
0.5
NS
0.1£¬1.0
4¡æ,22¡æ
X
>31d
17
remifentanil hydrochloride
0.025£¬0.25
NS
, http://www.100md.com 1
b
23¡æ
X
>4h
18
±½Ì¼Ëá˳°¢Çú¿âï§
0.1£¬2£¬5
5%GS
1
b
23¡æ£¬¸ßµÍÕնȹâ
X
, °ÙÄ´Ò½Ò©
>4h
19
TPN(»òPN)
NS
0.03£¬0.3£¬1
b
ÊÒΣ¬ÈÕ¹âµÆÏÂ
Y
>4 8h
20£¬21
4¦¤
CsA
1.5
, °ÙÄ´Ò½Ò©
NS
0.32
b,d
ÊÒΣ¬ÈÕ¹âµÆÏÂ
X
?
22
ÑÎËá¶à°Í°·
0.8
NS
0.32
b,d
ÊÒΣ¬ÈÕ¹âµÆÏÂ
, °ÙÄ´Ò½Ò©
X
>5h
22
¸ÎËØÄÆ
100u/ml
NS£¬5%GS
0.32
b,d
ÊÒΣ¬ÈÕ¹âµÆÏÂ
X
>5h
22
5¦¤
, °ÙÄ´Ò½Ò©
Æ»¹ûÖ¡¢éÙÖ¡¢¹û¾Æ¡¢Ó£ÌÒ
ÒûÁÏ¡¢Ì¼ËáÀàÈíÒûÁÏ
0.067-2
d
-3¡«28¡æ
Y
>1h
23£¬24
ÑÎËáÀ×ÄáÌ涡
0.2£¬2.0
5%GS
0.03£¬0.1£¬0.3
, °ÙÄ´Ò½Ò©
b
23¡æ
Y
>4h
8£¬25
6¦¤
µØÈûÃ×ËÉ
0.20£¬0.40
NS£¬5%GS
0.10£¬0.2£¬0.4£¬0.64[ HT6¡±¡½
a
2¡«6¡æ£¬23¡æ
Y
, °ÙÄ´Ò½Ò©
>48h
26¡«28
ÀÍÀÎ÷ãú
0.004
5%GS
0.016,0.08
d
25¡æ
Y
>24h
26
aldesleukin(ÖØ×é°×½éËØ-2)
33800IU/ml
, °ÙÄ´Ò½Ò©
5%GS
0.7
b
ÊÒΣ¬ ÈÕ¹âµÆÏÂ
Z
>2h
29
amifostine
10
5%GS
1
b
23¡æ
, °ÙÄ´Ò½Ò©
X
>4h
30
×¢£ºa-Ö±½Ó»ìºÏÓÚPVC´üÄÚ£»b-Ä£ÄâÊäҺװÖÃY²¿µÈÌå»ý»ìºÏÖüÓÚPVC´üÖÐ £»c-ÔÚ¾Û ÒìÎì¶þÏ©ÊäÒº±ÃÒ©³ØÖУ»d-²£Á§ÈÝÆ÷£»X-Íâ¹Û£»Y-Íâ¹Û¼°º¬Á¿£»Z-Íâ¹Û¡¢º¬Á¿¼°ÉúÎïЧ¼Û£» 1¦¤-Ond¡¢ÑÎËᰢùËØ¡¢´ï¿¨°ÍàºÈýÒ©ÅäÎ飬30¡æ¡¢ÈÕ¹âµÆÏ¡¢PVC´üÄÚÎȶ¨4¡«8h£¬¾ÛÒìÎì ¶þÏ©ÊäÒº±ÃÒ©³ØÖÐÎȶ¨24hÒÔÉÏ£»2¦¤-Ond¡¢ÑÎËᰢùËØ¡¢ÁòË᳤´ºÐ¼îÈýÒ©ÅäÎ飬30¡æ£¬ÈÕ ¹âµÆÏ£¬a»òcÈÝÆ÷ÄÚ¾ùÎȶ¨24hÒÔÉÏ£»3¦¤-Ond 1mg/mlÓëÃ×ŵÅäÄÜ1mg/ml NSÈÜÒºÅäÎéÎÞ³Áµí £»4¦¤-CsAÔÚNSÖÐ΢Á£³¬ÏÞ£¬¼ÓÈëOndºó΢Á£ÎÞÃ÷ÏÔÔö¼Ó£»5¦¤-Ond¼ÓÈëÈȲè(75¡«85¡æ)Öм´ ¿Ì±ä»ì×Ç£»6¦¤-¸ßŨ¶ÈµÄOnd(0.64mg/ml)ÓëµØÈûÃ×ËÉ(0.40mg/ml)ÔÚ¾Û±ûϩעÉäÆ÷ÖгÁµí(µÍ Ũ¶ÈÎÞ)£¬¸÷Ũ¶ÈÔÚ¹¤Òµ¾ÛÖ¬CR3´üÄÚÎȶ¨48hÒÔÉÏ
, http://www.100md.com
Óɸ½±í¿ÉÖª£¬OndÔÚ³£ÓÃŨ¶ÈÏ¿ÉÓëÐí¶àÒ©ÎïÅäÎéʹÓã¬Õâ¶Ô¼õÉÙ»¼Õß±»´©´Ì´ÎÊý¡¢Ò½ÎñÈË Ô±¹¤×÷Á¿¡¢»¼Õß²»±ØÒªÒºÌåÉãÈë¾ù¾ßÓлý¼«µÄÁÙ´²ÒâÒå¡£µ«Ó¦ÓÃÖÐӦעÒâÅäÎéÔÊÐíµÄŨ¶ÈºÍ Îȶ¨Ê±ÏÞ¡£OndÒ»°ã²»ÄÜÓëÃ×ŵÅäÄÜÅäÎ飬ÓëµØÈûÃ×ËÉÅäÎé²»ÄÜʹÓþ۱ûϩעÉäÆ÷¾ß£¬Ond¿É ¿Ú·þÓÃÒ©µ«²»ÄܼÓÈëÈȲèÖÐÒûÓã¬ÊÇ·ñÄÜÓë»·æßËØA(CsA)ÅäÎéÉв»Ã÷È·¡£
²Î¿¼ÎÄÏ×
1£¬Ðì¼ÃƼ£¬ÕŹ𷼣¬Õżø.°Âµ¤Î÷¡עÉäÒºÔÚ4ÖÖ ÊäÒºÖеÄÎȶ¨ÐÔ.ÖйúÁÙ´²Ò©Ñ§ÔÓÖ¾£¬1997£¬6(1)¡Ã31.
2£¬Bosso JA,Prince RA,Fox JL.Stability of on dansetron hydrochloride in injectable solutions at -20,5,25¡æ.Am J Hosp Pharm,19 92,49¡Ã2225.
3£¬Thee SS,Jeona EWS,Chin A,et al.Stability of ondanstron hydrochloride stored in a disposable elastomeric in fu sion device at 4¡æ.Am J Hosp Pharm,1993,50¡Ã1920.
, °ÙÄ´Ò½Ò©
4£¬ÍõÃ÷ÖÙÕª.ÑÎËá°Âµ¤Î÷¡ÓëÎåÖÖ¿¹Ö×ÁöÒ©µÄÅäÎé Îȶ¨ÐÔ.¹úÍâÒ½Ò©-ºÏ³ÉÒ©¡¢Éú»¯Ò©¡¢ÖƼÁ·Ö²á£¬1997£¬18(3)¡Ã189.
5£¬Stewart JT,Warren FW,King DT,et al.Stability of ondansetron hydrochloride,doxorubicin hydrochloride,and dacar bazine or vincristine sulfate in elastomeric portable infusion devices and polyv inyl chloride bags.Am J Health-Syst Pharm,1997,54¡Ã915.
6£¬Fleming RA,Olsen DJ,Savage PD,et al .Stability of ondansetron hydrochloride and cyclophosphamide.Am J Health- Syst Pharm,1995,52(5)¡Ã516.
, °ÙÄ´Ò½Ò©
7£¬Ðì¼ÃƼ£¬Õżø£¬ÕŹð·¼.°ºµ¤Ë¾Çí×¢Éä¼ÁÓë»·Á× õ£°·×¢Éä¼ÁµÄÅäÎéÎȶ¨ÐÔ.ÖйúҽԺҩѧÔÓÖ¾£¬1997£¬17(6)¡Ã263.
8£¬Burm JP,Jhee SS,Chin A,et al. Stability of paclitaxel with ondansetron hydrochloride or ranitidine hydrochlori de during simulated Y-site administration.Am J Hosp Pharm,1994,51¡Ã1201.
9£¬Trissel LA,Martinez JF.Turbidimetric as sessment of the compatibility of taxol with 42 other drugs during simulated Y-s ite injection.Am J Hosp Pharm,1993,50¡Ã300.
, °ÙÄ´Ò½Ò©
10£¬Henry DW,Marshall JL,Nazzaro D,et al .Stability of cisplatin and ondansetron hydrochloride in admixtures for continuo us infusion.Am J Health-Syst Pharm,1995,52¡Ã2570.
11£¬Trissel LA,Martinez JF.Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.Am J H ealth-Syst Pharm,1996,53¡Ã1041.
12£¬Chung KC,Moon YSK,Chin A,et al.Compa tibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration.Am J Health-Syst Pharm,1995,52¡Ã1554.
, °ÙÄ´Ò½Ò©
13£¬Bosso JA,Prince RA,Fox JL,et al.Compatibility of ondansetron hydrochloride with fluconazole,ceftazidime,azt reonam,and cefazolin sodium under simulated Y-site conditions.Am J Hosp Pharm,1 994,51¡Ã389.
14£¬Trissel LA,Martinez JF.Compatibility of aztreona m with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm,1995,52¡Ã1086.
15£¬Patel PR.Compatibility of meropenam with commonl y used injectable drugs.Am J Health-Syst Pharm,1996,53¡Ã2853.
, °ÙÄ´Ò½Ò©
16£¬Hutchings SR,Rusho Wj,Tyler LS.Compatibility of cefmetazole sodium with commonly used drugs during Y-Site delivery.Am J Health -Syst Pharm,1996,53¡Ã2185.
17£¬Trissel LA,Xu QY,Martinez JF,et al.C ompatibility and stability of ondansetron hydrochloride with morphine sulfate an d with hydromorphine hydrochloride in 0.9% sodium chloride injection at 4,22,and 32¡æ.Am J Hosp Pharm,1994,51¡Ã2142.
18£¬Trissel LA,Gilbert DL,Martinez JF,et al.Compatibility of remifentanil hydrochloride with selected drugs during simul ated Y-site administration.Am J Health-Syst Pharm,1997,54¡Ã2192.
, °ÙÄ´Ò½Ò©
19£¬Trissel LA,Martinez JF,Gilbert DL.Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administr ation.Am J Health-Syst Pharm,1997,54¡Ã1735.
20£¬Kirkham JC,Rutherford ET,Cunningham GN,et al.Stability of ondansetron hydrochloride in a total parenteral nutrient a dmixture.Am J Health-Syst Pharm,1995,52¡Ã1557
21£¬Trissel LA,Gilbert DL,Martinez JF,et al.Compatibility of parenteral nutrient solutions with selected drugs during si mulated Y-site administration.Am J Health-Syst Pharm,1997,54¡Ã1295.
, http://www.100md.com
22£¬Najari Z,Rusho Wj.Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.Am J Health-Syst Pharm,19 97,54¡Ã181.
23£¬Graham CL,Dukes GE,Fox JL,et al.Stab ility of ondansetron hydrochloride injection in extemporaneously prepared oral s olutions.Am J Hosp Pharm,1993,50¡Ã106.
24£¬Yamreudeewong W,Danthi SN,Hill RA,et al.Stability of ondansetron hydrochloride injection in various beverages.Am J H ealth-Syst Pharm,1995,52¡Ã2011.
, http://www.100md.com
25£¬Pompilio FM,Fox JL,Inagaki K,et al.S tability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazo le during simulated Y-site administration.Am J Hosp Pharm,1994,51¡Ã394.
26£¬Mcguire TR,Narducci WA,Fox JL.Compatibility an d stability of ondansetron hydrochloride,dexamethasone,and lorazepam in injectab le solutions.Am J Hosp Pharm,1993,50(7)¡Ã1410.
27£¬Evrard B,Ceccato A,Gaspard O,et al.S tability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride injection and in 5% dextrose injection.Am J Health-Syst Pharm, 1997,54¡Ã1065.
, http://www.100md.com
28£¬Hagan RL,Mallett MS,Fox JL.Stability of ondanset ron hydrochloride and dexamethasone sodium phosphate in infusion bags and syring es for 32 days.Am J Health-Syst Pharm,1996,53¡Ã1431
29£¬Alex S,Gupta SL,Minor JR,et al.Compa tibility and activity of aldesleukin(recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration:Evaluation of three metho ds.Am J Health-Syst Pharm,1995,52¡Ã2423.
30£¬Trissel LA,Martinez JF.Compatibility of amifosti ne with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm,1995,52¡Ã2208.
ÊÕ¸åÈÕÆÚ£º1998-04-06, http://www.100md.com